Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Nab-paclitaxel with SBRT for Resectable Pancreatic Cancer
NCT03492671Phase 2Recruiting
- Sponsor
- Loma Linda University
- Start
- Jul 2019
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Loma Linda University. Started Jul 2019; status: recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03492671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492671.